Abstract
Photodynamic therapy (PDT) was discovered in 1900 by Raab, and has since emerged as a promising tool for treating diseases characterized by unwanted cells or hyperproliferating tissue (e.g., cancer or infectious disease). PDT consists of the light excitation of a photosensitizer (PS) in the presence of O(2) to yield highly reactive oxygen species. In recent years, PDT has been improved by the synthesis of targeted bioconjugates between monoclonal antibodies and PS, and by investigating PS biodistribution and PD. Here, we provide a comprehensive review of major developments in PS-immunoconjugate-based PDT and the bioanalysis of these agents, with a specific emphasis on anticancer and antimicrobial PDT.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Infective Agents / analysis
-
Anti-Infective Agents / chemical synthesis
-
Anti-Infective Agents / pharmacology*
-
Antibodies, Monoclonal / analysis
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
Antineoplastic Agents / analysis
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Biological Assay*
-
Immunoconjugates / analysis
-
Immunoconjugates / immunology
-
Immunoconjugates / pharmacology*
-
Photochemotherapy*
-
Photosensitizing Agents / analysis
-
Photosensitizing Agents / chemical synthesis
-
Photosensitizing Agents / pharmacology*
-
Tissue Distribution
Substances
-
Anti-Infective Agents
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Immunoconjugates
-
Photosensitizing Agents